Skip to main content
Windlas Biotech Limited logo

Windlas Biotech Limited — Investor Relations & Filings

Ticker · WINDLAS ISIN · INE0H5O01029 LEI · 3358008HGGLMCSC4GP83 BSE.NS Manufacturing
Open in API
Filings indexed 432 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country IN India
Listing BSE.NS WINDLAS

About Windlas Biotech Limited

https://www.windlasbiotech.com

Windlas Biotech Limited is a Contract Development and Manufacturing Organization (CDMO) providing integrated services from formulation development to commercial-scale production. The company specializes in manufacturing solid and liquid oral dosage forms, including tablets, capsules, sachets, and liquid orals. Its operations encompass three primary business verticals: CDMO services for domestic and multinational firms, trade generics, and over-the-counter (OTC) brands. Windlas maintains advanced research and development facilities focused on process optimization and complex generic formulations. The product portfolio covers diverse therapeutic areas such as gastrointestinal, cardiovascular, anti-diabetic, and respiratory health. The company emphasizes scalable manufacturing solutions and adherence to global quality standards to support the product lifecycles of its pharmaceutical partners.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 75% confidence The document is a formal intimation under Regulation 30 of SEBI LODR notifying stock exchanges and investors that an audio recording of the investor/analyst conference call has been uploaded and that the transcript will follow. It does not contain actual financial results, substantive data, or the full call transcript itself, nor is it an earnings highlights release. It is a regulatory announcement, fitting the fallback category for general compliance notifications under SEBI listing rules.
2026-05-22 English
Audio recording of Investors/ Analyst conference call on the audited consolidated and standalone financial results of the Company for the quarter and financial year ended March 31, 2026,.
Regulatory Filings Classification · 85% confidence The document is a letter under SEBI Regulation 30 (Listing Obligations and Disclosure Requirements) notifying stock exchanges that the audio recording of an investor/analyst conference call has been uploaded to the company website and that the transcript will follow. It does not contain actual financial results or substantial financial statements, nor does it include the transcript itself. It is simply a regulatory disclosure/intimation. This falls into the general Regulatory Filings category (RNS).
2026-05-22 English
Updates
Regulatory Filings Classification · 85% confidence The document is a regulatory disclosure sent to stock exchanges under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements, providing details on the grant of employee stock options under the company’s ESOS 2023 and Plan 2025. It does not contain full financial statements, voting results, or legal proceedings, nor is it a management or annual report. Rather, it is a general compliance announcement about share‐based employee benefit grants. This fits the “Regulatory Filings” category.
2026-05-21 English
Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 regarding grant of Stock Options/ Units under 'WBL Employee Stock Option ....
Share Issue/Capital Change Classification · 80% confidence The document is a formal disclosure to the stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015, informing investors about the grant of employee stock options and units under two schemes. It does not contain any financial statements, results, or requests for votes—rather it details a capital change (future share issuances upon exercise of options). This aligns with the definition of Share Issue/Capital Change (SHA).
2026-05-21 English
'Windlas Biotech Limited Reports its Q4 and FY26 Financial Results'
Earnings Release Classification · 90% confidence The document is a press release titled “Windlas Biotech Limited Reports its Q4 and FY26 Financial Results,” sent to stock exchanges to announce unaudited quarterly and full-year financial highlights (revenue, EBITDA, PAT, margins, etc.). It contains summary metrics and business commentary but does not include full statutory financial statements or detailed MD&A. This matches the definition of an Earnings Release (initial announcement of periodical financial results). FY 2026
2026-05-21 English
Press Release
Earnings Release Classification · 87% confidence The document is a press release announcing unaudited Q4 and FY26 financial results, submitted to stock exchanges and containing key metrics (revenue, EBITDA, PAT, margins) along with management commentary. It is an initial announcement of quarterly and full year financial results rather than a detailed quarterly report or Excel supplement. Hence, it matches the definition of an Earnings Release (ER). FY 2026
2026-05-21 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.